US FDA Reveals DTC Enforcement Approach In Letter For AstraZeneca’s FluMist Ad

 
• By Derrick Gingery
  
FluMist, an intranasal flu vaccine, was the subject of a CBER advertising violation letter. (Shutterstock)

More from Marketing & Advertising

More from United States